A previous study from our group indicated that BX795, a TBK1 inhibitor, suppressed the expression of inflammatory cytokines, such as IL-6 and IL-10, in a nonalcoholic steatohepatitis mouse model; however, the relevant mechanism was not defined (21). Here, IL10 is linked to metabolic dysfunction-associated steatohepatitis.